Abstract
We appreciate Larcher et al. for their interest in our study and for their review of the literature on cefiderocol as a treatment for non-fermenting Gram-negative bacilli (NFGNB) infections ( 1 Larcher R Laffont-Lozes P Loubet P Laureillard D Naciri T Sotto A Re: ‘real world clinical outcome of cefiderocol for treatment of multidrug resistant non-fermenting gram-negative bacilli infections’ by Hoellinger et al. Clin Microbiol Infect. 2023 Feb 2; S1198-743X (00047-2) Google Scholar ). Our case series supplements those already published, despite the inherent limitations of this type of data ( 2 Hoellinger B Simand C Jeannot K Garijo C Cristinar M Reisz F et al. Real-world clinical outcome of cefiderocol for treatment of multidrug-resistant non-fermenting, gram negative bacilli infections: a case series. Clin Microbiol Infect. 2022 Nov 18; S1198-743X (00571-00577) Google Scholar ). Nevertheless, some points deserve to be highlighted. Re: ‘Real world clinical outcome of cefiderocol for treatment of multidrug-resistant nonfermenting gram-negative bacilli infections' by Hoellinger et al.Clinical Microbiology and InfectionPreviewWe read with deep interest the letter by Hoellinger et al. [1], in which the outcomes of ten patients treated with cefiderocol for multidrug-resistant (MDR) nonfermenting gram-negative bacilli infections were reported. In this work, patients treated with cefiderocol exhibited dramatically high 30-day mortality, clinical failure, and microbiological failure rates at 60%, 80%, and 60%, respectively. The authors stated that the high rate of treatment failure could be explained by a delayed effective antimicrobial therapy in most of the patients (8/10), the risk of error in cefiderocol susceptibility assessment, the high rate of heteroresistance to cefiderocol, and the high proportion of bloodstream infections (BSIs) and immunocompromised patients. Full-Text PDF
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
